Greenwich LifeSciences flags release with FLAMINGO-01 clinical update
GLSI•Cash and burn-rate outlook
- Q2 2026 burn rate expected near $2 million; cash balance estimated at $8.9 million as of June 30, 2026.
Phase III FLAMINGO-01 trial updates
- Greenwich LifeSciences posted clinical updates on its Phase III FLAMINGO-01 trial of GLSI-100 to prevent breast cancer recurrences.
- DSMB review in May 2026 recommended the study continue without modification.
- Trial redesign targets HR 0.55; interim analyses at 28 events, 56 events; study end at 133 events; enrollment may run up to 2,000 patients.
- Protocol change expands eligibility beyond HLA-A*02; company expects a 2.22x faster enrollment rate.
